Assessment of the Relationship Between Serum Prostate-Specific Antigen Level and Serum Fasting Glucose, Total Cholesterol and Neutrophil-Lymphocyte Ratio in Men Aged 50-70 Years with Prostate-Specific Antigen Level 0-10 ng/mL without Prostate Cancer Diagnosis

Bora İrer MD
İzmir Metropolitan Municipality Esrefpaşa Hospital, Clinic of Urology, İzmir, Turkey

Abstract

Objective: To evaluate the relationship between serum prostate-specific antigen (PSA) level and total cholesterol, fasting blood glucose, and neutrophil-lymphocyte ratio (NLR) in men without prostate cancer.

Materials and Methods: Between 2010 and 2017, 2631 male participants aged 50-70 years with a serum PSA level of 0-10 ng/mL were included from a population of 4643 healthy males who participated in a health screening program conducted by the İzmir Metropolitan Municipality Esrefpaşa Hospital in the district villages of İzmir. Participants’ serum PSA, fasting blood glucose, total cholesterol levels, and NLR were retrospectively assessed. Participants were grouped as those with high and low serum PSA levels, high and low glucose levels, and high and low cholesterol levels. Differences between the groups in terms of serum PSA levels, serum total cholesterol, glucose, and NLR were analyzed.

Results: The mean age of the participants was 60.2±5.4 years and the mean serum PSA level was 1.28±1.20 ng/mL. The mean PSA value was higher in the high cholesterol group (1.36±1.33 vs 1.19±1.02, p<0.001) compared to the low cholesterol group, and the mean PSA value in the high glucose group was lower than in the low glucose group (1.08±0.86 vs 1.32±1.25, p<0.001). Compared to the normal PSA group, the high PSA group had higher mean cholesterol level (208.6±39.9 vs 203.3±41.8, p<0.001) and NLR (2.17±1.00 vs 2.06±0.89, p=0.039), but lower glucose level (108.5±32.5 vs 117.2±51.0, p=0.004). Serum PSA level was positively correlated with total cholesterol and NLR (r=0.074 and p<0.001, r=0.050 and p=0.011), and negatively with glucose level (r=-0.084 and p<0.001).

Conclusion: Evaluation of total cholesterol, fasting glucose, and NLR, which may be associated with serum PSA levels, may help urologists when investigating elevated serum PSA levels in asymptomatic men aged 50-70 years who have not been diagnosed with prostate cancer.

Keywords: Prostate-specific antigen testing, prostate cancer, screening

Introduction

Globally, prostate cancer is the second leading cause of cancer-related mortality in males (1,2). The incidence of prostate cancer has risen in many countries over the past two decades due to prostate cancer screening utilizing the serum prostate-specific antigen (PSA) test (3,4,5). Although PSA testing is not currently recommended as a routine screening tool for prostate cancer...
Serum PSA levels may be affected by a number of factors other than prostate disorders in men who have not been diagnosed with prostate cancer. Although there are studies in the literature investigating the effects of obesity, serum glucose, total cholesterol, and triglyceride levels on serum PSA levels, the results of these studies are contradictory (10,11,12,13). Today, many men aged 50-70, despite not being diagnosed with diabetes or hypercholesterolemia, are found to have high blood glucose or total cholesterol level when tested for PSA.

In addition to numerous other parameters, neutrophil-lymphocyte ratio (NLR) has recently been studied as a marker of the inflammatory response in solid organ tumors because it is easily determined. NLR is an established marker of progression and poor prognosis in lung, pancreatic, colorectal, ovarian, and prostate cancer (14). Although there are many studies demonstrating a relationship between NLR and the risk of prostate cancer diagnosis, recurrence, and progression (15,16), few studies have shown a relationship between serum PSA levels and NLR in patients without prostate cancer (14).

The aim of this study was to determine the relationship between serum PSA level and fasting blood glucose, total cholesterol, and NLR in men aged 50-70 years without prostate cancer.

### Materials and Methods

Of 4643 healthy males who presented for health screening conducted by the Izmir Metropolitan Municipality Eşrefpaşa Hospital in the district villages of Izmir between 2010 and 2017, 2631 participants aged 50-70 with a serum PSA level of 0-10 ng/mL were included in the study. The participants’ serum PSA, fasting blood glucose, total cholesterol levels, and NLR were retrospectively evaluated. Patients with prostate cancer and patients receiving medical treatment for urinary tract infections, BPH, diabetes, and hyperlipidemia were excluded from the study. Relationships between serum PSA level and fasting glucose, total cholesterol, and NLR were assessed. Participants were grouped as those with and without high glucose (>126 mg/dL) (17) and high cholesterol (>200 mg/dL) (18), and the differences between groups and their association with serum PSA levels were assessed. In addition, differences in serum total cholesterol, glucose, and NLR between participants with and without serum PSA level over 2.5 ng/mL (8) were evaluated.

Because the study was designed as a retrospective chart review, ethics committee approval and informed consent were not obtained. However, the participants provided informed consent during the health screening.

### Results

The mean age of the 2631 male participants included in the study was 60.2±5.4 years and their mean serum PSA level was 1.28±1.20 ng/mL. The participants’ demographic data, serum glucose and total cholesterol levels, and NLR are shown in Table 1. Men with high cholesterol had significantly higher mean serum PSA levels than men without high cholesterol (p<0.001). However, mean serum PSA level was significantly lower in participants with high serum glucose levels when compared to those without high serum glucose (p<0.001) (Table 2). Comparison of groups with and without elevated PSA revealed higher total cholesterol and NLR and lower mean fasting glucose levels among men with elevated serum PSA levels (p<0.001, p=0.039, and p=0.004, respectively) (Table 3). There were statistically significant but weak positive correlations between serum PSA level and total cholesterol and NLR (r=0.074 and p<0.001; r=0.050 and p=0.011) (Table 3). There was a significant but weak negative correlation between serum PSA level and fasting blood glucose (r=-0.084 and p<0.001).

### Table 1. Demographic data of the participants

<table>
<thead>
<tr>
<th>Number of participants</th>
<th>2631</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean age (range), years</td>
<td>60.2±5.4 (50-69)</td>
</tr>
<tr>
<td>Mean PSA (range), ng/mL</td>
<td>1.28±1.20 (0.10-9.32)</td>
</tr>
<tr>
<td>Mean cholesterol (range), mg/dL</td>
<td>203.9±41.6 (83-437)</td>
</tr>
<tr>
<td>Mean glucose (range), mg/dL</td>
<td>116.2±49.3 (46-554)</td>
</tr>
<tr>
<td>Mean neutrophil/lymphocyte ratio</td>
<td>2.07±0.91</td>
</tr>
<tr>
<td>E elevated glucose (&gt;126 mg/dL), (n, %)</td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>2153, 81.8%</td>
</tr>
<tr>
<td>Yes</td>
<td>237, 11.3%</td>
</tr>
<tr>
<td>E elevated cholesterol (&gt;200 mg/dL), (n, %)</td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>1368, 48.0%</td>
</tr>
<tr>
<td>Yes</td>
<td>1263, 52.0%</td>
</tr>
</tbody>
</table>

PSA: Prostate-specific antigen

### Table 2. Comparison of age and serum prostate-specific antigen level between groups

<table>
<thead>
<tr>
<th>Elevated glucose</th>
<th>Elevated cholesterol</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Yes</strong></td>
<td><strong>No</strong></td>
</tr>
<tr>
<td>Age, years (mean ± SD)</td>
<td>61.2±5.1</td>
</tr>
<tr>
<td>PSA, ng/mL (mean ± SD)</td>
<td>1.08±0.86</td>
</tr>
</tbody>
</table>

PSA: Prostate-specific antigen, SD: Standard deviation
In this study, we showed that serum PSA levels were inversely correlated with fasting blood glucose and that glucose levels were lower in those with elevated PSA. Werny et al. (27) reported lower PSA levels in diabetic patients compared to non-diabetic patients. Müller et al. (10) showed that greater diabetes severity was associated with larger decreases in PSA. Similarly, Sun et al. (28) showed that patients with type 2 diabetes had lower PSA levels and that prediabetes was associated with higher PSA levels. Although the participants in the present study were not diagnosed with diabetes, the results were similar to those of previous studies. In addition, we found that participants with elevated PSA had lower fasting blood glucose levels. In the literature, molecular studies describing this inverse relationship between PSA and fasting blood glucose have shown a decline in blood testosterone level and increase in estrogen level in diabetes, which may result in a decrease in androgen-dependent PSA synthesis and secretion (29,30).

Some previous studies have shown that systemic inflammation plays a role in the development and progression of cancer and that prostate cancer is associated with infectious agents, chronic infections, and dietary and hormonal inflammatory factors (31,32). NLR is one of the markers of systemic inflammation and has been shown to correlate with the diagnosis, prognosis, and progression of prostate cancer (15,16); however, the relationship between systemic inflammation and serum PSA levels in men without prostate cancer remains unclear. McDonald et al. (14) demonstrated in their study that NLR was associated with elevated serum PSA. In our study, there was a positive correlation between elevated serum PSA and NLR, and NLR was higher in the group with PSA elevation. NLR elevation is associated with higher concentrations of many pro-inflammatory cytokines. These pro-inflammatory cytokines cause cellular DNA damage which can lead to cell death or cancer development (32).

### Study Limitations

The main limitations of this study are its retrospective nature, the lack of advanced testing to establish other possible etiologies of PSA elevation, and the lack of follow-up results for the participants.

### Conclusion

The results of this study indicate that serum PSA elevation may be associated with high total cholesterol level, high NLR, and low fasting blood glucose level. Taking total cholesterol level, fasting glucose level, and NLR into account may help urologists when evaluating elevated serum PSA in asymptomatic men aged 50-70 who have never been diagnosed with prostate cancer. However, better planned studies that analyze the results of patient follow-up are needed to establish the exact relationship between these factors and serum PSA levels in asymptomatic men.

### Ethics

**Ethics Committee Approval:** Because the study was designed as a retrospective chart review, ethics committee approval was not obtained.
Informed Consent: Informed consent was obtained during the health screening in which the data analyzed in the study were collected. Separate informed consent was not sought for this retrospective chart review study.

Peer-review: Externally peer-reviewed.

Financial Disclosure: The author declared that this study received no financial support.

References


